P. D. Grimm, J. C. Blasko, J. E. Sylvester, R. M. Meier, and C. W. , 10-year biochemical (prostate-specific antigen) control of prostate cancer with (125)I brachytherapy, Int. J. Radiat. Oncol. Biol. Phys, vol.51, pp.31-40, 2001.

L. Potters, C. Morgenstern, and E. Calugaru, 12-year outcomes following permanent prostate brachytherapy in patients with clinically localized prostate cancer, J. Urol, vol.179, pp.20-24, 2008.
DOI : 10.1016/j.juro.2008.03.133

N. N. Stone, L. Potters, and B. Davis, Customized dose prescription for permanent prostate brachytherapy: insights from a multicenter analysis of dosimetry outcomes, Int. J. Radiat. Oncol. Biol. Phys, vol.69, pp.1472-1477, 2007.

M. J. Zelefsky, D. Kuban, and L. Levy, Multi-institutional analysis of long-term outcome for stages T1-T2 prostate cancer treated with permanent seed implantation, Int. J. Radiat. Oncol. Biol. Phys, vol.67, pp.327-333, 2007.

D. Amico, A. V. Whittington, and R. Malkowicz, Biochemical outcome after radical prostatectomy, external beam radiation therapy, or interstitial radiation therapy for clinically localized prostate cancer, JAMA, vol.280, pp.969-974, 1998.

L. Harlan, O. Brawley, F. Pommerenke, P. Wali, and B. Kramer, Geographic, age, and racial variation in the treatment of local/regional carcinoma of the prostate, J. Clin. Oncol. Off. J. Am. Soc. Clin. Oncol, vol.13, pp.93-100, 1995.

D. W. Lin, M. Porter, and B. Montgomery, Treatment and survival outcomes in young men diagnosed with prostate cancer: a Population-based Cohort Study, Cancer, vol.115, pp.2863-2871, 2009.

. Insee, La situation démographique en, 2012.

R. J. Burri, A. Y. Ho, K. Forsythe, J. A. Cesaretti, N. N. Stone et al., Young men have equivalent biochemical outcomes compared with older men after treatment with brachytherapy for prostate cancer, Int. J. Radiat. Oncol. Biol. Phys, vol.77, pp.1315-1321, 2010.

A. Gomez-iturriaga-pina, J. Crook, J. Borg, G. Lockwood, and N. Fleshner, Median 5 year follow-up of 125iodine brachytherapy as monotherapy in men aged<or=55 years with favorable prostate cancer, Urology, vol.75, pp.1412-1416, 2010.

E. Y. Shapiro, S. Rais-bahrami, C. Morgenstern, B. Napolitano, L. Richstone et al., Long-term outcomes in younger men following permanent prostate brachytherapy, J. Urol, vol.181, pp.1665-1671, 2009.

G. S. Merrick, K. E. Wallner, and W. Butler, Brachytherapy in men aged < or = 54 years with clinically localized prostate cancer, BJU Int, vol.98, pp.324-328, 2006.

K. E. Wallner, J. Blasko, and M. J. Dattoli, Prostate brachytherapy made complicated. Evaluating cancer status 1997

F. A. Critz, W. H. Williams, J. B. Benton, A. K. Levinson, C. T. Holladay et al.,

, Prostate specific antigen bounce after radioactive seed implantation followed by external beam radiation for prostate cancer, J. Urol, vol.163, pp.1085-1089, 2000.

M. D. Mitchell, R. Swindell, T. Elliott, J. P. Wylie, C. M. Taylor et al., Analysis of prostate-specific antigen bounce after I(125) permanent seed implant for localised prostate cancer, Radiother. Oncol, vol.88, pp.102-107, 2008.

A. O. Naghavi, T. J. Strom, and K. Nethers, Clinical implications of a prostate-specific antigen bounce after radiation therapy for prostate cancer, Int. J. Clin. Oncol, vol.20, pp.598-604, 2015.

N. Patel, L. Souhami, and J. Mansure, Prostate-specific antigen bounce after high-doserate prostate brachytherapy and hypofractionated external beam radiotherapy, Brachytherapy, vol.13, pp.450-455, 2014.

M. Caloglu, J. Ciezki, and C. Reddy, PSA bounce and biochemical failure after brachytherapy for prostate cancer: a study of 820 patients with a minimum of 3 years of follow-up, Int. J. Radiat. Oncol. Biol. Phys, vol.80, pp.735-741, 2011.

M. B. Bernstein, N. Ohri, and J. Hodge, Prostate-specific antigen bounce predicts for a favorable prognosis following brachytherapy: a meta-analysis, J. Contemp. Brachytherapy, vol.5, pp.210-214, 2013.

R. Mazeron, A. Bajard, and X. Montbarbon, Permanent 125I-seed prostate brachytherapy: early prostate specific antigen value as a predictor of PSA bounce occurrence, Radiat. Oncol, vol.7, pp.46-57, 2012.

W. S. Bice, B. R. Prestidge, J. J. Prete, and D. F. Dubois, Clinical impact of implementing the recommendations of AAPM Task Group 43 on permanent prostate brachytherapy using 125I

, American Association of Physicists in Medicine, Int. J. Radiat. Oncol. Biol. Phys, vol.40, pp.1237-1241, 1998.

G. S. Merrick, M. Zelefsky, and K. Sylverster, Prostate Low-Dose Rate Task Group

W. Cavanagh, J. C. Blasko, P. D. Grimm, and J. E. Sylvester, Transient elevation of serum prostate-specific antigen following (125)I/(103)Pd brachytherapy for localized prostate cancer, Semin. Urol. Oncol, vol.18, pp.160-165, 2000.

. Roach-m-3-rd, G. Hanks, and H. Thames, Defining biochemical failure following radiotherapy with or without hormonal therapy in men with clinically localized prostate cancer: recommendations of the RTOG-ASTRO Phoenux Consensus Conference, Int. J. Radiat. Oncol. Biol. Phys, vol.65, pp.965-974, 2006.

M. C. Abramowitz, T. Li, and M. K. Buyyounouski, The Phoenix definition of biochemical failure predicts for overall survival in patients with prostate cancer, Cancer, vol.112, pp.55-60, 2008.

J. Ciezki, C. Reddy, and J. Garcia, PSA kinetics after prostate brachytherapy: PSA bounce phenomenon and its implications for PSA doubling time, Int. J. Radiat. Oncol. Biol. Phys, vol.64, pp.512-517, 2006.

C. Patel, M. Elshaikh, and K. Angermeier, PSA bounce predicts early success in patients with permanent iodine-125 prostate implant, Urology, vol.63, pp.110-113, 2004.

S. H. Aaltomaa, V. V. Kataja, T. Lahtinen, J. E. Palmgren, and T. Forsell, Eight years experience of local prostate cancer treatment with permanent I125 seed brachytherapy-morbidity and outcome results, Radiother. Oncol, vol.91, pp.213-216, 2009.

N. H. Mehta, M. Kamrava, P. C. Wang, M. Steinberg, and J. Demanes, Prostate-specific antigen bounce after high-dose-rate monotherapy for prostate cancer, Int. J. Radiat. Oncol. Biol. Phys, vol.86, pp.729-733, 2013.

K. A. Hinnen, E. M. Monninkhof, J. J. Battermann, J. Van-roermund, and S. J. Frank,

M. Vulpen, Prostate specific antigen bounce is related to overall survival in prostate brachytherapy, Int. J. Radiat. Oncol. Biol. Phys, vol.82, pp.883-888, 2012.

A. F. Prestigiacomo and T. A. Stamey, Physiological variation of serum prostate specific antigen in the 4.0 to 10.0 ng./ml. range in male volunteers, J. Urol, vol.155, pp.1977-1980, 1996.

F. Critz, W. Williams, and A. Levinson, Prostate specific antigen bounce after simultaneous irradiation for prostate cancer: the relationship to patient age, J. Urol, vol.170, pp.1864-1867, 2003.

M. Morita, J. L. Lederer, T. Fukagai, M. Shimada, and H. Yoshida, PSA bounce phenomenon after transperineal interstitial permanent prostate brachytherapy for localized prostate cancer. Nihon Hinyokika Gakkai Zasshi Jpn, J. Urol, vol.95, pp.609-615, 2004.

M. Tambas, F. Agaoglu, and A. Iribas, Conventionally Fractionationed Volumetric Arc Therapy versus Hypofractionated Stereotactic Body Radiotherapy: Quality of Life, Side Effects, and Prostate-Specific Antigen Kinetics in Localized Prostate Cancer. Value Health Reg, Issues, vol.10, pp.91-99, 2016.

N. Tanaka, I. Asakawa, and K. Fujimoto, Minimal percentage of dose received by 90% of the urethra (%UD90) is the most significant predictor of PSA bounce in patients who underwent low-dose-rate brachytherapy (LDR-brachytherapy) for prostate cancer, BMC Urol, vol.12, pp.28-34, 2012.

C. Hackett, S. Ghosh, and R. Sloboda, Distinguishing prostate-specific antigen bounces from biochemical failure after low-dose-rate prostate brachytherapy, J. Contemp. Brachytherapy, vol.6, pp.247-253, 2014.

M. Anwar, V. Weinberg, Z. Seymour, I. J. Hsu, M. Roach et al., Outcomes of hypofractionated stereotactic body radiotherapy boost for intermediate and highrisk prostate cancer, Radiat. Oncol, vol.11, pp.8-15, 2016.

J. Crook, C. Gillan, I. Yeung, A. L. Mclean, M. Lockwood et al., PSA kinetics and PSA bounce following permanent seed prostate brachytherapy, Int. J. Radiat. Oncol. Biol. Phys, vol.69, pp.426-433, 2007.

H. Kanzaki, M. Kataoka, and A. Nishikawa, Kinetics differences between PSA bounce and biochemical failure in patients treated with 125I prostate brachytherapy, Jpn. J. Clin. Oncol, vol.45, pp.688-694, 2015.

H. J. Kim, J. H. Phak, and W. C. Kim, Clinical outcomes of whole pelvis radiotherapy and stereotactic body radiotherapy boost for intermediate-and high-risk prostate cancer, Asia Pac. J. Clin. Oncol, vol.13, pp.21-27, 2016.

A. K. Singh, P. Guion, and R. Susil, Early observed transient prostate-specific antigen elevations on a pilot study of external beam radiation therapy and fractionated MRI guided high dose rate brachytherapy boost, Radiat. Oncol, vol.1, pp.28-32, 2006.

M. Ghilezan, S. Park, and H. Ye, A Modified Phoenix Biochemical Failure (BF) Definition to Account for PSA Bounce Phenomenon for Prostate Cancer Patients Treated with Brachytherapy (BT), Proc. Am. Soc. Radiat. Oncol. 51st Annu. Meet, vol.75, p.311, 2009.

C. Chira, D. Taussky, and N. Gruszczynski, Unusually high prostate-specific antigen bounce after prostate brachytherapy: Searching for etiologic factors, Brachytherapy, vol.2013, pp.12-603

R. Makarewicz, A. Lebioda, J. Terlikiewicz, M. Biedka, and T. Wisniewski, PSA bouncing after brachytherapy HDR and external beam radiation therapy: a study of 121 patients with minimum 5-years follow-up, J. Contemp. Brachytherapy, vol.1, pp.92-96, 2009.

G. S. Merrick, W. M. Butler, K. E. Wallner, J. H. Lief, A. Hinerman-mulroy et al.,

, Prostate-specific antigen (PSA) velocity and benign prostate hypertrophy predict for PSA spikes following prostate brachytherapy, Brachytherapy, vol.2, pp.181-188, 2003.

Y. Yamamoto, C. Offord, and G. Kimura, Tumour and immune cell dynamics explain the PSA bounce after prostate cancer brachytherapy, Br. J. Cancer, vol.115, pp.195-202, 2016.

M. J. Zelefsky, K. E. Wallner, and C. C. Ling, Comparison of the 5-year outcome and morbidity of three-dimensional conformal radiotherapy versus transperineal permanent iodine-125 implantation for early-stage prostatic cancer, J. Clin. Oncol. Off. J. Am. Soc. Clin. Oncol, vol.17, pp.517-522, 1999.

N. N. Stone and R. G. Stock, Complications following permanent prostate brachytherapy, Eur. Figure, vol.3

, Ces éléments doivent être diffusés en raison de la place croissante que prend la curiethérapie seule ou en complément de la radiothérapie externe dans la stratégie de prise en charge des cancers de la prostate, p.-

R. De and L. A. Thèse,